Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0032463 (polycythemia vera)
 3,374 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We developed a quantitative enzyme immunoassay for human MRP-8/MRP-14, neutrophil cytosolic proteins with calcium-binding and bacteriastatic properties. MRP-8/MRP-14 concentrations were measured in the plasma of 23 healthy volunteers and in 75 patients with hematological disorders. These proteins were detected in plasma of healthy blood donors with mean +/- standard deviation 167 +/- 114 ng/ml. MRP-8/MRP-14 plasma levels ranged from 435 to 13280 ng/ml in patients with chronic myeloid leukemia (CML), from 50 to 7570 ng/ml in chronic lymphoid leukemia (CLL), from 450 to 2790 ng/ml in polycythemia vera (PV), and were significantly higher than in healthy blood donors (P < 0.01 for CML and P < 0.05 for others). In CML patients MRP-8/MRP-14 levels strongly correlated with total blood WBC count (r = 0.82) and with neutrophilic granulocyte (NG) count (r = 0.80). Correlation of these values in PV amounted to r = 0.70 and r = 0.46, respectively. In CLL patients MRP-8/MRP-14 levels strongly correlated with total WBC count (r = 0.92), but not with the NG count. We suggest that MRP-8/MRP-14 quantitation may serve as a marker of neutrophil pool turnover in some hematological disorders.
 ...
PMID:Enzyme-linked immunosorbent assay for human MRP-8/MRP-14 proteins and their quantitation in plasma of hematological patients. 896 12

The gene and protein expression profiles in myeloproliferative neoplasms (MPNs) may reveal gene and protein markers of a potential clinical relevance in diagnosis, treatment and prediction of response to therapy. Using cDNA microarray analysis of 25,100 unique genes, we studied the gene expression profile of CD34+ cells and granulocytes obtained from peripheral blood of subjects with essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). The microarray analyses of the CD34+ cells and granulocytes were performed from 20 de novo MPN subjects: JAK2 positive ET, PV, PMF subjects, and JAK2 negative ET/PMF subjects. The granulocytes for proteomic studies were pooled in 4 groups: PV with JAK2 mutant allele burden above 80%, ET with JAK2 mutation, PMF with JAK2 mutation and ET/PMF with no JAK2 mutation. The number of differentially regulated genes was about two fold larger in CD34+ cells compared to granulocytes. Thirty-six genes (including RUNX1, TNFRSF19) were persistently highly expressed, while 42 genes (including FOXD4, PDE4A) were underexpressed both in CD34+ cells and granulocytes. Using proteomic studies, significant up-regulation was observed for MAPK and PI3K/AKT signaling regulators that control myeloid cell apoptosis and proliferation: RAC2, MNDA, S100A8/9, CORO1A, and GNAI2. When the status of the mTOR signaling pathway related genes was analyzed, PI3K/AKT regulators were preferentially up-regulated in CD34+ cells of MPNs, with down-regulated major components of the protein complex EIF4F. Molecular profiling of CD34+ cells and granulocytes of MPN determined gene expression patterns beyond their recognized function in disease pathogenesis that included dominant up-regulation of PI3K/AKT signaling.
 ...
PMID:Microarray and Proteomic Analyses of Myeloproliferative Neoplasms with a Highlight on the mTOR Signaling Pathway. 2627 51